AP2212A - Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. - Google Patents

Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.

Info

Publication number
AP2212A
AP2212A AP2006003675A AP2006003675A AP2212A AP 2212 A AP2212 A AP 2212A AP 2006003675 A AP2006003675 A AP 2006003675A AP 2006003675 A AP2006003675 A AP 2006003675A AP 2212 A AP2212 A AP 2212A
Authority
AP
ARIPO
Prior art keywords
monophosphonamidates
bisphosphonamidates
phosphonates
treatment
viral diseases
Prior art date
Application number
AP2006003675A
Other languages
English (en)
Other versions
AP2006003675A0 (en
Inventor
Xiaqin Cheng
Gary P Cook
Manoj C Desai
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2006003675A0 publication Critical patent/AP2006003675A0/xx
Application granted granted Critical
Publication of AP2212A publication Critical patent/AP2212A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2006003675A 2003-12-30 2004-12-29 Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. AP2212A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53374503P 2003-12-30 2003-12-30
US59098704P 2004-07-26 2004-07-26
US60659504P 2004-09-01 2004-09-01
PCT/US2004/043969 WO2005066189A1 (en) 2003-12-30 2004-12-29 Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases

Publications (2)

Publication Number Publication Date
AP2006003675A0 AP2006003675A0 (en) 2006-08-31
AP2212A true AP2212A (en) 2011-03-01

Family

ID=34753695

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003675A AP2212A (en) 2003-12-30 2004-12-29 Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.

Country Status (27)

Country Link
US (5) US7553825B2 (de)
EP (2) EP1716162B1 (de)
JP (2) JP4949852B2 (de)
KR (2) KR20120080240A (de)
CN (2) CN1950383B (de)
AP (1) AP2212A (de)
AT (1) ATE478082T1 (de)
AU (2) AU2004312546B2 (de)
BR (1) BRPI0418251C1 (de)
CA (1) CA2550222C (de)
CY (2) CY1111050T1 (de)
DE (1) DE602004028763D1 (de)
DK (2) DK2204374T3 (de)
EA (1) EA011304B1 (de)
ES (2) ES2389602T3 (de)
HR (3) HRP20100626T1 (de)
IL (1) IL176407A (de)
IS (1) IS2994B (de)
NO (2) NO338001B1 (de)
NZ (1) NZ548771A (de)
PL (3) PL2204374T3 (de)
PT (2) PT2204374E (de)
RS (2) RS51476B (de)
SG (1) SG149075A1 (de)
SI (2) SI2204374T1 (de)
WO (1) WO2005066189A1 (de)
ZA (1) ZA200606049B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7193081B2 (en) 2002-05-13 2007-03-20 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of PMEA and PMPA
WO2004037161A2 (en) * 2002-05-13 2004-05-06 Metabasis Therapeutics, Inc. Cyclic prodrugs of pmea one of its analogues
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
JP2006505583A (ja) 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2005066189A1 (en) 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
EP1753762B1 (de) * 2004-06-08 2014-03-19 Metabasis Therapeutics, Inc. Lewissäurevermittelte synthese von cyclischen estern
WO2007002808A1 (en) * 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof
WO2007002912A2 (en) * 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
SI2020996T1 (sl) * 2006-05-16 2012-03-30 Gilead Sciences Inc Postopek in sestavki za zdravljenje hematološkihmalignosti
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
AU2007269557B2 (en) * 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008008397A2 (en) * 2006-07-14 2008-01-17 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102309984B (zh) * 2011-07-22 2013-05-01 华东师范大学 一种磷酸酰胺类双功能催化剂及其合成方法
ES2734495T3 (es) * 2011-12-22 2019-12-10 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
SI2970346T1 (sl) 2013-03-15 2018-12-31 The Regents Of The University Of California Aciklični diestri nukleozid fosfonata
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
EP3623364A1 (de) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Organische verbindungen und deren verwendungen
WO2015161785A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
PT3194411T (pt) 2014-09-15 2022-06-06 Univ California Análogos de nucleótidos
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
US10087209B2 (en) * 2015-04-28 2018-10-02 Ku Leuven Research & Development Antiviral compounds, a process for their preparation, and their use for treating viral infections
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
EP3875462A1 (de) 2015-09-15 2021-09-08 The Regents of The University of California Nukleotidanaloga
EP3386512B1 (de) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antivirale phosphodiamid-prodrugs von tenofovir
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2017124896A1 (zh) * 2016-01-19 2017-07-27 四川海思科制药有限公司 一种核苷类似物的磷酰胺酯前药及其应用
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
EP3515923A1 (de) * 2016-09-23 2019-07-31 Katholieke Universiteit Leuven Prodrugs von fluorierten acyclischen nukleosidphosphonaten
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
EP3558322B1 (de) * 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antivirale benzyl-amin-phosphodiamidverbindungen
US10519159B2 (en) 2016-12-22 2019-12-31 Merck Sharp & Dohme Corp. Antiviral aliphatic ester prodrugs of tenofovir
CN108276444A (zh) * 2017-01-06 2018-07-13 米文君 一类新的化合物及其用途
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
JP7436374B2 (ja) * 2018-09-28 2024-02-21 広栄化学株式会社 アミデート化合物の製造方法及びアミデート化合物
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
BR112023002164A2 (pt) 2020-08-07 2023-03-14 Gilead Sciences Inc Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico
WO2024020127A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia
CN118652277A (zh) * 2024-08-19 2024-09-17 成都工业学院 一种用于治疗癌症疾病的化合物的制备方法
CN118652276B (zh) * 2024-08-19 2024-10-15 成都工业学院 一种用于治疗癌症疾病的化合物的制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528490C2 (de) * 1975-06-26 1983-04-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung saurer Protease
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル，アーノルド 含リンプロドラッグ
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
EP1244668B1 (de) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
WO2002008241A2 (en) * 2000-07-21 2002-01-31 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
DE10236294A1 (de) * 2001-08-17 2003-02-27 Alstom Switzerland Ltd Gasversorgungskontrolleinrichtung einer Gasspeicherkraftanlage
CN1168449C (zh) * 2002-12-23 2004-09-29 梁有国 抗人乳头瘤病毒感染的药物
WO2005066189A1 (en) 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN ET AL.: "In vivo anti-papilomavirus activity of nucleoside analogues inciudinh cidofovir on CRPV-induced rabbit papillomas" ANTIVIRAL RESEARCH, vol. 48, 2000, pages 131-142 *
KEITH ET AL.: "Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, no. 7, July 2003 (2003-07), pages 2193-2198 *
SNOECK ET AL.: "Antivaccinia Activities of Acyclic Nucleoside Phosphonate Derivatives in Epithelial Cells and Organotypic Cultures" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 11, November 2002 (2002-11), pages 3356-3361 *

Also Published As

Publication number Publication date
NZ548771A (en) 2010-05-28
PT1716162E (pt) 2010-11-24
CA2550222A1 (en) 2005-07-21
PT2204374E (pt) 2012-09-17
PL380828A1 (pl) 2007-03-19
JP4949852B2 (ja) 2012-06-13
IS8516A (is) 2006-06-21
EP1716162A1 (de) 2006-11-02
SI2204374T1 (sl) 2012-09-28
BRPI0418251B1 (pt) 2019-09-24
US20050222090A1 (en) 2005-10-06
AU2011200141B2 (en) 2012-02-16
US8088754B2 (en) 2012-01-03
BRPI0418251B8 (pt) 2019-10-08
DE602004028763D1 (de) 2010-09-30
AU2004312546A1 (en) 2005-07-21
PL212403B1 (pl) 2012-09-28
KR101214257B1 (ko) 2012-12-21
US20090149400A1 (en) 2009-06-11
IL176407A0 (en) 2006-10-05
JP2011137029A (ja) 2011-07-14
AU2011200141A1 (en) 2011-02-03
CN1950383B (zh) 2010-06-09
US20060030545A1 (en) 2006-02-09
RS51476B (sr) 2011-04-30
IS2994B (is) 2018-03-15
IL176407A (en) 2012-12-31
AU2004312546B2 (en) 2010-10-14
SG149075A1 (en) 2009-01-29
HRP20120699T1 (hr) 2012-09-30
HK1146061A1 (en) 2011-05-13
PL1716162T3 (pl) 2011-02-28
HRP20060254A2 (en) 2006-10-31
CN101816664B (zh) 2012-04-18
CY1111050T1 (el) 2015-06-11
WO2005066189A1 (en) 2005-07-21
EA011304B1 (ru) 2009-02-27
CA2550222C (en) 2013-05-28
CN1950383A (zh) 2007-04-18
ES2389602T3 (es) 2012-10-29
EA200601263A1 (ru) 2006-12-29
NO338001B1 (no) 2016-07-18
BRPI0418251C1 (pt) 2021-05-25
CN101816664A (zh) 2010-09-01
ZA200606049B (en) 2008-01-08
NO20150615L (no) 2005-07-01
DK2204374T3 (da) 2012-09-10
DK1716162T3 (da) 2011-01-10
EP2204374B1 (de) 2012-06-13
SI1716162T1 (sl) 2010-12-31
KR20120080240A (ko) 2012-07-16
HK1097276A1 (en) 2007-06-22
CY1113103T1 (el) 2016-04-13
US20060046981A1 (en) 2006-03-02
EP2204374A1 (de) 2010-07-07
KR20060129360A (ko) 2006-12-15
EP1716162B1 (de) 2010-08-18
US8268802B2 (en) 2012-09-18
HRP20100626T1 (hr) 2011-03-31
NO20063479L (no) 2006-10-02
PL2204374T3 (pl) 2012-11-30
ATE478082T1 (de) 2010-09-15
US20090291922A1 (en) 2009-11-26
RS52433B (sr) 2013-02-28
JP2007517065A (ja) 2007-06-28
BRPI0418251A (pt) 2007-04-17
AP2006003675A0 (en) 2006-08-31
NO338040B1 (no) 2016-07-25
US7553825B2 (en) 2009-06-30
ES2350983T3 (es) 2011-01-28

Similar Documents

Publication Publication Date Title
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
EG25148A (en) Process for the manufacture of 1,2-dichloroethane.
EG25281A (en) Process for the manufacture of 1,2-dichloroethane.
EP1594512A4 (de) Verbindungen zur behandlung von virusinfektionen
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AP2005003232A0 (en) Combination therapy for hyperproliferative diseases.
EP1545558A4 (de) 1, 3, 5-triazine zur behandlung von viruserkrankungen
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
AP2006003514A0 (en) Piperazine derivatives for the treatment of HIV infections.
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
HRP20050328A2 (en) Process for the preparation of (s,s)-cis-2-benzhyd
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
ZA200606780B (en) Compounds for the treatment of diseases
SI1663244T1 (sl) Pteridinski derivati za zdravljenje bolezni, povezanih s TNF-alfa
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.
AU2003284212A8 (en) Process for the preparation of (s,s)-cis-2-phenyl-3-aminopiperidine
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
ITUD20030080A1 (it) Procedimento per effettuare transazioni commerciali.